Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

@article{FreitasJunior2012VisceralLT,
  title={Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?},
  author={Lucio H Freitas-Junior and Eric Chatelain and Helena Andrade Kim and Jair L Siqueira-Neto},
  journal={International journal for parasitology. Drugs and drug resistance},
  year={2012},
  volume={2},
  pages={
          11-9
        }
}
Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 97 CITATIONS, ESTIMATED 59% COVERAGE

Visceral Leishmaniasis in Southeastern Iran: A Narrative Review

  • Iranian journal of parasitology
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis

  • European Journal of Clinical Microbiology & Infectious Diseases
  • 2014
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Need for sustainable approaches in antileishmanial drug discovery

Sarah Hendrickx, G. Caljon, Louis Maes
  • Parasitology Research
  • 2019
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 16 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 98 REFERENCES

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

  • Antimicrobial agents and chemotherapy
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Leishmaniasis: drugs in the clinic, resistance and new developments.

  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.

  • Biochimica et biophysica acta
  • 2002
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL